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Abstract
The differentiation of CD4 helperT cells into specialized effector lineages has provided a powerful model for under-
standing immune cell differentiation. Distinct lineages have been defined by differential expression of signature
cytokines and the lineage-specifying transcription factors necessary and sufficient for their production. The trad-
itional paradigm of differentiation towardsTh1 and Th2 subtypes driven byT-bet and GATA3, respectively, has been
extended to incorporate additional T cell lineages and transcriptional regulators. Technological advances have
expanded our view of these lineage-specifying transcription factors to the whole genome and revealed unexpected
interplay between them. From these data, it is becoming clear that lineage specification is more complex and plastic
than previous models might have suggested. Here, we present an overview of the different forms of transcription
factor interplay that have been identified and how T cell phenotypes arise as a product of this interplay within
complex regulatory networks. We also suggest experimental strategies that will provide further insight into the
mechanisms that underlieT cell lineage specification and plasticity.
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INTRODUCTION
T helper cell differentiation and lineages:
TheTh1/Th2 paradigm
Differentiation of naı¨ve CD4þ T cells into different
helper subtypes allows tailoring of the immune re-
sponse to different pathogens and constitutes a
powerful model system for the study of cell specifi-
cation. Different helper T cells function in part
through the secretion of cytokines that modulate
the function of other immune cell types.
Differential production of these cytokines has pro-
vided the foundation for helper T cell classification
from which transcriptional regulatory mechanisms
have been characterized. The definition of different
helper T cell subtypes began with the description of
two distinct classes that exhibited differences in cyto-
kine production that were stable during passage [1].
This demonstrated that the specialization of helper
T cells was deterministic rather than stochastic and
led to the Th1–Th2 paradigm for differentiation of
specialized T helper lineages. Under this paradigm,
Th1 cells, which differentiate in the presence of
IFNg and IL-12, produce the signature cytokine
IFNg to activate macrophages and cytotoxic
CD8þ cells to clear intracellular pathogens. Th2
cell differentiation is induced by IL-4 and the cells
also secrete this cytokine, leading to activation of the
humoral immune response and clearance of extracel-
lular parasites [2]. The concept that Th1 and Th2
cells are separate lineages was reinforced by the dis-
covery of the transcriptional ‘master regulators’
T-bet (TBX21) [3] and GATA3 [4] as being neces-
sary and sufficient for the development of Th1 and
Th2 cells, respectively. T-bet was found to be spe-
cifically induced in Th1 cells, in which it binds and
activates Ifng, whereas GATA3 in Th2 cells binds and
Catherine M. Evans holds a BSc from the University of York, which included 1 year at the Sanger Institute. She is currently
conducting her PhD at University College London (UCL).
Richard G. Jenner holds a PhD from University College London (UCL) and completed his postdoctoral research with Rick Young
at the Whitehead Institute. He is currently a Reader in Molecular Biology at UCL and leads a research group in transcriptional and
chromatin regulation of cell differentiation.
Corresponding author. Richard G. Jenner, Division of Infection and Immunity and UCL Cancer Institute, University College
London, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6BT, UK. Tel: þ44 (0) 20 7679 6815; Fax: þ44 (0) 20
7209 0470; E-mail: r.jenner@ucl.ac.uk
BRIEFINGS IN FUNCTIONAL GENOMICS. VOL 12. NO 6. 499^511 doi:10.1093/bfgp/elt025
 The Author 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
 at U
CL Library Services on Septem
ber 16, 2014
http://bfgp.oxfordjournals.org/
D
ow
nloaded from
 
activates the Il4/Il5/Il13 cytokine locus. Other T-box
and GATA factors play key roles in embryonic de-
velopment, such as the heart and limbs, suggesting
parallels between classical developmental processes
and T cell activation in adult mammals [5].
Growing numbers of helperTcell
subtypes and lineage plasticity
The Th1–Th2 paradigm was subsequently extended
to encompass a number of additional subsets. Th17
cells, named for their signature production of IL-17,
differentiate through TGF-b and IL-6 signalling and
clear extracellular bacteria and fungi [2]. In contrast,
induced regulatory T cells (iTreg) differentiate under
TGF-b and IL-2 signalling and suppress immune
responses [6]. An additional subset of CD4þ Treg,
naturally occurring Treg (nTreg), exit the thymus in
parallel to naı¨ve CD4 T helper precursors [7]. Each
of these subsets is associated with an immune path-
ology when their differentiation and function is dys-
regulated [8] suggesting they play key individual
roles in the immune response. ‘Master regulator’
transcription factors have also been identified for
these lineages; RORgt for Th17 [9], FOXP3 for
iTreg and nTreg [10–12]. Follicular helper T (Tfh)
cells, which express the ‘master regulator’ BCL6
[13–15], Th9 [16] and Th22 [17] cell lineages have
also been described.
Recent findings also suggest that these T cell lin-
eages may not be as immutable as once thought. For
example, Th17 cells can become exclusive IFNg
producers and Tfh cells can be re-differentiated to
make IFNg, IL-4 or IL-17 (reviewed in [18–20]).
Tregs can also convert to effector (non-regulatory
helper) cells in inflammatory environments. Even
stable GATA3 expressing Th2 cells can acquire
Th1 functionality after transfer to mice subsequently
infected with LCMV [21]. Such plasticity may reflect
the frequent co-expression of what had been con-
sidered lineage-specific master regulatory transcrip-
tion factors. For example, FOXP3 has been found
to be co-expressed with GATA3, T-bet or RORgt
and GATA3 and T-bet have been found together
within the same cells (Table 1).
The continued identification of T cell subsets and
the plasticity that exists between them has led to
debate over the true meaning of a T cell lineage.
When viewed from a transcriptional regulation
stand-point, it would appear that the assumption
that expression of a transcription factor equates to a
Table 1: Co-expressed lineage-specifying transcription factors
Factor 1 Factor 2 Cell phenotype Condition References
FOXP3 GATA3 Treg In vivo during steady state. [22]
Treg GI tract and skin during inflammation. Human in vitro following TCR
engagement.
[23]
Treg UponTCR stimulation with IL-2 in vitro. [24]
FOXP3 T-bet Treg (Th1^Treg intermediate) In vivo duringTh1-polarizing infection. [25^27]
Treg In response to IFNg and IL-27 duringTh1-polarizing infection. [28]
FOXP3 RORgt Th17^Treg intermediate Lamina propria and in vitro in response toTGF-b and TCR stimulation. [29, 30]
Treg Ex vivo during steady state, intestinal inflammation, viral infection and
cancer.
[31]
Treg^Th17 intermediate In vivo in autoimmune diabetes model (NOD). [32]
FOXP3 BCL6 FollicularTreg In germinal centres after immunization with antigen. [33, 34]
T-bet BCL6 Tfh^Th1 transitional state In germinal centres duringTh1-polarizing infection. [35, 36]
Th1 During in vitroTh1 differentiation (when IL-2 is limiting). [37, 38]
T-bet GATA3 Th1 During in vitro differentiation of human cells. [39^41,]
Th1 Human ex vivo steady state and in in vitro generated Th2 clones uponTCR
stimulation.
[42]
Th2þ1 In vivo after transfer of Th2 cells to mice subsequently infected with
LCMV and in vitro through IL-12 and type I and II IFN signalling.
[21]
T-bet RORgt Th17 Human in vitro uponTCR stimulation. [43]
Th17 In vitro with IL-23, IL-6 and IL-1b and in vivo in a brain inflammation model
(EAE).
[44]
Th17/1 intermediate Cells from autoimmune juvenile inflammatory arthritis patients ex vivo. [45]
Th17 Human in vitro after priming with Candida albicans. [46]
Th17 In vitro withTGF-b3 and IL-6 signalling. [47]
GATA3 RORgt Th2 memory Cells from allergic asthma patients ex vivo. [48]
All aremouseunless otherwise specified.GI tract, gastrointestinal tract;MS,multiple sclerosis; EAE; experimental allergic encephalomyelitis;NOD,
non-obese diabetic; LCMV, lymphocytic choriomeningitis virus.
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specific phenotype can be misleading. The concept
of ‘master regulator’ transcription factors, although
useful in identifying critical regulatory factors
would seem to underestimate the complexity of
helper T cell function. To understand how cell
phenotype arises, we must first understand the inter-
play between the multiple transcription factors that
are co-expressed within the cell.
Functional genomics approaches are playing a key
role in this work. No longer limited to the study of a
small number of cytokine and cell surface markers,
T cell phenotypes can now be characterized and
understood through measurements of gene expres-
sion, epigenetic modifications and chromatin struc-
ture at a genomic level. This has expanded our
understanding of transcription factor function from
the signature cytokines to the rest of the genome and
illustrated how T cell differentiation truly is a gen-
omic event.
A number of modes of transcription factor inter-
play are evident from this data (Figure 1); factors
binding early and acting as pioneers for the lin-
eage-specifying proteins (Figure 1A), antagonism ex-
pressed as mutually exclusive binding to the same site
(Figure 1B), synergism between factors (Figure 1C),
competition for a shared co-factor (Figure 1D), re-
distribution of one factor by another (Figure 1E) and
modulation of a regulators activity by another
(Figure 1F).
PIONEER FACTORS
Different cell types arise in development from the
differential use of regulatory elements such as enhan-
cers and it would seem reasonable to assume that the
lineage-specifying factors such as T-bet, GATA3 and
FOXP3 initiate this cell-type specific enhancer acti-
vation. But instead it appears that other pioneering
factors function to first set up these enhancer reper-
toires (Figure 1A).
The induction of lineage-specifying transcription
factors is initiated by cytokines that signal through
Figure 1: Modes of transcription factor interplay. (A) Pioneering transcription factors prepare the epigenetic land-
scape, allowing other factors to bind to regulatory elements. For example, STAT1 and STAT4 allow the subsequent
binding of T-bet and Th1differentiation. (B) Transcription factors can antagonize the function of others, for example,
STAT5, associated with Treg differentiation, suppresses Th17 cell function by blocking STAT3 binding and activation
of the Il17a locus. (C) Lineage-specific transcription factors, such as FOXP3, synergize with co-factors (such as Ets)
to enhance gene expression and produce a more robust T cell subset signature. (D) Competition for a mutual co-fac-
tor. For example RORgt and FOXP3 compete for binding to RUNX1, inhibiting each other’s activity.
(E) Redistribution of a factor to new sites.T-bet sequesters GATA3 away from itsTh2 target genes and redistributes
it to Th1-associated T-bet targets. (F) The activity of a transcription factor can be modulated by other factors,
for example, repressive activity is endowed uponT-bet by BCL6.
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receptors to activate signal transducer and activator
and transcription (STAT) family members, thereby
directly linking the cytokine environment to tran-
scriptional regulation. Different cytokines lead to ac-
tivation of different STATs, which begin the
specification of different lineages. As a simplistic
model, STAT4 (activated by IL-12 [49]) leads to
Th1 differentiation (STAT1, activated by IFNg,
also plays a role [50]), STAT6 (activated by IL-4
[51]) to Th2, STAT3 (activated by IL-6, IL-21 and
IL-23) to Th17 [52], and STAT5 (activated by IL-2)
to Treg [53]. STATs bind at genes encoding lineage-
specifying cytokines and transcription factors and are
necessary for their expression and can thereby be
considered as initiating the process of lineage speci-
fication. Functional genomics studies have revealed
that STATs are also vital for determining enhancer
function across the genome [54–56]. Using ChIP-
Seq, Vahedi et al. [55] revealed that Th1 enhancer
elements (defined by Th1-specific p300 binding in
the absence of H3K4me3) were enriched for binding
of STAT1 and STAT4 in Th1 cells and instead for
STAT6 in Th2 cells. Consistent with a role for
STATs in generating these enhancer landscapes,
p300 binding was dependent on STAT1 or
STAT4 at over half of Th1 enhancers, and on
STAT6 at three-quarters of Th2 enhancers [55].
Similarly, STAT3 is required for p300 binding at
regulatory elements in Th17 cells [56].
STATs appear to play a more fundamental role
in lineage-specifying enhancer activity than the lin-
eage-specifying factors that are subsequently upregu-
lated. P300 binding was only found to be dependent
on T-bet at 17% of Th1-specific enhancers, com-
pared to 58% being dependent on either STAT1
or STAT4. Furthermore, overexpression of T-bet
only recovered p300 binding at 23% of Th1-specific
STAT4-dependent enhancers [55]. Similarly,
RORgt has a limited effect on p300 binding and
on H3K4 di- and tri-methylation [56].
However, arguing against an all-encompassing
role for STATs in defining enhancer activity,
H3K4me1 at these sites is not dependent on
STATs [55] and only one-quarter of STAT-bound
genes exhibit STAT4- or STAT6-dependent histone
H3 lysine 4 trimethylation (H3K4me3; initiation),
K27me3 (poised repression) or K36me3 (elongation)
[54], suggesting they are not sufficient for normal
patterns of epigenetic modification and gene activity.
Other factors, such as AP-1 and NFAT family
members, which are activated downstream of the
T cell receptor (TCR), have been implicated in
functioning as general acting pioneer factors at en-
hancers in Th1 and Th2 cells [55], Th17 cells [56]
and in Tregs [57]. In addition, IRF4 and BATF are
important for initiating enhancer activity (measured
by p300 binding and open chromatin) in non-
polarized cells, at which STAT3 and RORgt then
bind in Th17 cells [56]. Indeed, RORgt was found
to be almost exclusively bound to sites also bound by
IRF4, BATF and STAT3 [56].
Transcription factors of the same structural family
can also act as pioneer factors for the lineage-specify-
ing factors. Samstein et al. [57] found that 98% of
FOXP3 binding sites were already accessible
(DNaseI hypersensitive) in FOXP3-negative CD4
cells. However, this doesn’t rule out that FOXP3
has other effects on enhancer function subsequent
to formation of an open chromatin structure.
Noting enrichment of Forkhead motifs at these
sites and evidence that another Forkhead family
member, FOXO1, also functions in Tregs, the
authors found that FOXO1 acts as a placeholder
for FOXP3, occupying sites in FOXP3-negative
CD4 T cells that are subsequently bound by
FOXP3. Moreover, FOXP3 binding resulted in
reduced FOXO1 binding and a reduction in gene
expression, suggesting that FOXP3 displaces the
FOXO1 placeholder. Samstein and colleagues also
identified binding of ELF1, ETS1 and Runx/Cbfb
at FOXP3 pre-accessible sites. These proteins inter-
act with FOXP3 [24], suggesting that co-factors can
also act as placeholders for the subsequent binding of
lineage-specifying factors.
Taken together, these studies suggest that the
major epigenetic changes that occur during T cell
polarization take place downstream of TCR ligation
and cytokine signalling before the lineage-specifying
factors are induced. The lineage-specifying factors
would then seem to act within this already estab-
lished epigenetic landscape to drive a smaller set of
more focused changes in gene expression pertinent
to the specific role of that particular lineage. This is
consistent with gene expression profiling data which
shows that the greatest extent of transcriptome
remodelling occurs during the early phases of
T cell activation [58, 59] and provides a potential
molecular basis for lineage plasticity.
Interplay between pioneer factors
TCR signalling occurs in concert with signals from
other receptors and, in vivo, cytokines are not
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provided to cells in isolation as they are during
in vitro experimental lineage specification. It is,
therefore, important to understand the interplay be-
tween pioneer factors activated by these different
pathways.
Comparison between ChIP-Seq datasets shows
that pioneer factors tend to bind to the same genes,
often at the same sites. As described above, FOXO1,
ETS1, ELF1 and Runx/Cbfb are often found at the
same positions along the genome in Treg precursors
[57] and IRF4, BATF and subsequently STAT3 bind
to the same sites in Th17 cells [56]. Although func-
tioning in different differentiation pathways, 50%
of STAT4 (Th1) and STAT6 (Th2) target genes are
bound by the other factor [54].
This shared binding can be both cooperative and
antagonistic. Both STAT4 and STAT1 induce T-bet
expression [50, 60]. Similarly, STAT5A/5B bind to
Th2 genes in addition to STAT6 [61–63] and
collaborate with STAT6 for the induction of Il4 pro-
duction and Th2-mediated inflammation [64].
Indeed, two-thirds of genes directly regulated by
STAT6 were found to also be regulated by
STAT5A [65]. Similarly, in Th17 cells, ChIP in
cells from genetically deficient mice reveals BATF
and IRF4 binding to be co-dependent [56].
In the context of Th17 differentiation, STAT5
has an antagonistic relationship with STAT3 [66].
STAT5 (induced by IL-2) competes with STAT3
(induced by IL-6) for binding to Il17a, leading to
loss of permissive histone modifications and a reduc-
tion in expression (Figure 1B—Antagonism). The
resultant expression level of Il17a depends on the
relative concentrations of IL-2 and IL-6. However,
in the absence of TGF-b and in the presence of IL-4,
STAT3 acts cooperatively, being required for
STAT6 binding to sites at Th2 genes [67]. In this
way, the interplay between the different STATs
allows the cell to sense complexities in the cytokine
environment and the resultant cell phenotype could
lie somewhere along a continuum rather than rep-
resenting a decisive differentiation decision.
LINEAGE-SPECIFYING
REGULATORSOPERATE
WITH CO-FACTORSAND IN
NETWORKS
Once the chromatin landscape has been prepared
by the pioneer transcription factors, the lineage-
specifying transcription factors take effect. These
proteins are associated with both the activation and
repression of target genes and these targets can vary
between cells. These differences in transcription
factor activity in different contexts are partly related
to the presence of co-factors, which can synergize
with or modulate lineage-specifying factor activity.
Co-factors that functionally cooperate with each of
the lineage-specific factors have been identified.
Although in some cases evidence of physical inter-
action or complex formation is lacking, these co-fac-
tors are necessary for optimal activation or repression
of lineage-specific target genes. These co-factors in-
clude ETS1, HLX and RUNX3 for T-bet [68–70],
GFI1, cMAF and DEC2 for GATA3 [71–74] and
RUNX1, BATF, IRF4 and FOSL1 for RORgt
[56, 75, 76].
Transcriptional regulatory networks
inTregs
Although the phenotypes caused by FOXP3-defi-
ciency suggest it is the ‘master regulator’ for Treg
cells, its interaction with co-factors seems to be
especially important for generation of the full Treg
gene expression program (Figure 1C—Synergy).
Rudra and colleagues [24] used biochemical methods
to identify the FOXP3 interactome. Over 300
FOXP3 potential co-factors were identified by
mass spectrometry. Of these, 27% had known roles
in transcriptional regulation. These included tran-
scription factors, such as RUNX1, NFATc2,
FOXP1, GATA3, STAT3, Ikaros, Aiolos and Ets,
many of which have previously been implicated in
Treg differentiation and co-occupy sites with
FOXP3 [57, 24]. Rudra et al. also noted that mem-
bers of this FOXP3 interactome target the Foxp3
gene and, reciprocally, that FOXP3 targets the
genes encoding its partner proteins.
Similar results were gathered by Fu and co-work-
ers, who used the context likelihood of relatedness
algorithm to ‘reverse-engineer’ the Treg transcrip-
tional network and to identify the relationship be-
tween FOXP3 and other transcription factors [77].
By comparing the gene expression profiles of Treg
and other helper T cells from various anatomical
locations and varying phenotypes, the authors iden-
tified a set of transcription factors that could account
for much of the Treg signature [77]. Loss and gain of
function experiments revealed that the Treg expres-
sion signature was robust; genetic deletion or
retroviral overexpression of any of the co-factors
individually had little effect, but overexpression of
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any one of a set of five factors (IRF4, GATA1, LEF1,
SATB1 and Eos) together with FOXP3 lead to a
strong synergistic establishment of the Treg signa-
ture. Consistent with the extent of the FOXP3
interactome, these factors were also found to interact
with FOXP3 and act to enhance FOXP3 binding to
already existing target sites to increase Treg gene
induction [77].
The number of potential FOXP3 co-factors
revealed by Rudra and colleagues [24], the ability
of multiple factors to work with FOXP3 to generate
the Treg expression signature as revealed by Fu et al.
[77], and the extensive cross-regulation between
FOXP3 and its co-factors revealed by both
studies demonstrate that FOXP3 forms the core
of a regulatory network containing multiple
feedback loops and redundancy between factors.
This may, therefore, allow robust induction of
a Treg phenotype from different T cell states in
varying immune environments [77]. Similar net-
works of factors have also been identified for Th17
cells [56, 78].
CO-EXPRESSIONOF
LINEAGE-SPECIFYING
TRANSCRIPTION FACTORS
It had been considered that each helper T cell lin-
eage had a corresponding master regulator factor
that was necessary and sufficient for its differenti-
ation, T-bet for Th1, GATA3 for Th2, FOXP3 for
Treg and so on. The importance of the pioneer
factors and the role of co-factors suggests that
these ‘master’ regulators are not as all-powerful as
perhaps thought and that they function within a
complex regulatory network to define cell state.
These master regulators should perhaps more cor-
rectly be referred to as lineage-specifying factors
[79]. To confound matters further, it has emerged
that expression of the lineage-specifying factors is
not restricted to a single lineage but that they are
frequently co-expressed with other lineage-specify-
ing factors outside of their canonical subset (Table
1, [2, 79]). Although initially considered to consti-
tute a transitional state during lineage commitment,
co-expression of lineage-specifying factors also
occurs in what appear to be stably committed
subset populations [79]. A key challenge therefore
is to understand how co-expression affects transcrip-
tion factor function, and the consequences this has
for cell phenotype and plasticity.
Co-expression of FOXP3 with effector
cell regulatorsçmodulation of Treg
properties
The effect of lineage-specifying factor co-expression
is perhaps best understood in Tregs, in which the
induction of effector lineage-specifying factors is
necessary to target immunosuppressive activity ap-
propriately. T-bet is upregulated in Tregs in response
to IFNg [25] or IL-27 [28]. These cells maintain
their suppressive activity in both scurfy [25] and
airway hyper-reactivity [26] mouse models with
T-bet acting to induce the Th1 homing receptor
CXCR3 [25]. Consistent with this, T-bet-positive
Tregs accumulate at sites of Th1-mediated inflam-
mation and T-bet is required for Treg homoeostasis
and function during type 1 inflammation [25].
This role for lineage-specifying factors for Tregs
to suppress inflammation associated with a specific
effector subset is also demonstrated by the require-
ment for GATA3 for Treg accumulation at inflamed
sites [23] and the increase in IL-4/5/13 producing
Th2 cells and inflammatory disorders in mice in
which Gata3 is specifically deleted in FOXP3-posi-
tive cells [22, 24]. Similarly, FOXP3þRORgtþ cells
express CD62L and traffic to the pancreas to suppress
effector T cells in a type I autoimmune diabetes
model [32], whereas FOXP3þBCL6þ cells express
the germinal-centre homing marker CXCR5 and
limit the extent of the germinal centre reaction
[33, 34]. Thus, FOXP3 appears to act dominantly,
inducing a Treg expression program, while the
co-expression of a lineage-specifying regulator, in
response to the cytokine microenvironment, acts
as a modulating agent to appropriately ‘polarize’
the suppressive activity.
What form does the interplay between FOXP3
and co-expressed lineage-specifying factors take?
FOXP3 interacts with GATA3, with ChIP revealing
GATA3 bound at sites at FOXP3 target genes [24].
Specific deletion of GATA3 in FOXP3-positive cells
demonstrates that the two proteins can either act
cooperatively or antagonistically, with GATA3 loss
tending to lead to downregulation of their shared
targets [24]. FOXP3 also interacts with RORgt,
with FOXP3 acting dominantly, interfering with
the ability of RORgt to activate its target genes
[29, 30]. FOXP3 contains the sequence LQALL
which matches the LxxLL interaction motif used
by nuclear co-activators and co-repressors required
for nuclear hormone receptor activity and therefore
FOXP3 may act in a dominant negative fashion to
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prevent RORgt function [80]. The antagonism be-
tween FOXP3 and RORgt is also played out
through physical competition for RUNX1, which
is required for both Th17 and Treg differentiation
[75, 81, 82]. Therefore, a common partner, such
as a Runx protein, can provide the pivot through
which transcription factor interplay is balanced
(Figure 1D—Competition).
Although FOXP3 can act dominantly over the co-
expressed effector regulator, changes in their relative
levels may shift the balance towards an effector cell
phenotype. FOXP3 repression of RORgt activity is
released upon treatment with the Th17-inducing
cytokines IL-6, IL-21 or IL-23 [30, 83]. Similarly,
T-bet positive Tregs can gain effector function
during Toxoplasma gondii infection [27]. Thus, al-
though FOXP3 can act dominantly, the co-expres-
sion of effector regulators also provides a degree of
plasticity between suppressor and effector function.
Interplay betweenT-bet, GATA3 and
RORgt
The co-expression between FOXP3 and the ‘master
regulators’ of effector cell lineages fits within a model
in which FOXP3 acts to impose suppressor function
upon the defined effector subtypes. Co-expression of
the classical lineage-specifying regulators T-bet,
RORgt and GATA3 is more difficult to reconcile
within a model in which each effector subtype is a
distinct terminally differentiated lineage but may
instead provide a mechanism for the functional plas-
ticity that is apparent between T cell effector subtypes.
RORgt can be co-expressed with either GATA3
or T-bet and in both cases this appears to be associated
with pathological outcomes. Th17 cells that co-
express T-bet can be generated in vitro by culture
in IL-6, IL-1b and IL-23 [44, 46] and their transfer
into an allergic encephalomyelitis mouse model leads
to more severe disease than conventional Th17 cells
[44, 47, 84]. Similarly, Th17-producing Th2 cells
were found to induce an influx of inflammatory
leukocytes and to exacerbate asthma [48]. Microarray
analysis shows that, similar to the role of T-bet in
Treg homing, the co-expression of T-bet and
RORgt creates a hybrid gene expression program,
which includes expression of the Th1 homing
marker CXCR3 [44, 47].
This blurring between the canonical effector lin-
eages has even extended to the paradigmatic Th1 and
Th2 subtypes. T-bet and GATA3 are co-expressed
in in vitro differentiated primary human Th1 cells
[39–41, 85] and in CCR5þ Th1 memory cells
[42]. Furthermore, although in vitro polarized
murine Th2 cells stably maintain a Th2 phenotype,
transfer into mice subsequently infected with
LCMV, or cultured in vitro with IL-12, IFNg,
IFNþ b and anti-IL-4, leads to co-expression of
GATA3 and T-bet in these cells [21].
To understand the interplay between T-bet and
GATA3 when they are co-expressed, we mapped
their binding across the genome in primary human
Th1 and Th2 cells using ChIP-Chip [40], and more
recently ChIP-Seq [41]. We found that GATA3 ex-
hibits a switch in its binding sites between Th2 and
Th1 cells. GATA3 binds to a unique set of enhancer
sites in Th2 cells and this is associated with Th2-
polarized expression of the associated genes. In Th1
cells, GATA3 is distributed away from these pos-
itions and instead occupies a new set of sites at
Th1 genes, which are also bound by T-bet
(Figure 1E—Redistribution). Interestingly, although
the Th2-specific sites contain a GATA motif, directly
bound by GATA3, the Th1-specific sites do not,
they only contain a T-box motif recognized by
T-bet. Using a T cell line model in which T-bet
and GATA3 could be expressed individually or
together, we found that expression of T-bet is suffi-
cient to induce GATA3 binding at Th1-specific sites,
indicating it is directly responsible for the redistribu-
tion of GATA3 in Th1 cells [41]. Thus, T-bet would
appear to act dominantly, sequestering GATA3 away
from Th2 genes to prevent the activation of these
genes in Th1 cells. This is consistent with the hy-
pothesis that T-bet is primarily repressive and func-
tions to block a default Th2 program [40, 86, 87].
How does T-bet cause a change in GATA3 bind-
ing? T-bet and GATA3 have been reported to dir-
ectly interact [88] and the T-bet-GATA3 complex
may only be able to bind to T-bet sites. Alternatively,
T-bet may be able to influence GATA3 binding
through RUNX3, which interacts with both T-bet
[70] and GATA3 and is necessary for T-bet repression
of Il4 [89, 90]. T-bet antagonism of GATA3 at Th2
genes may be reflected by the reported ability of T-
bet to block p300 binding at non-Th1 enhancer sites
[55], which suggests that T-bet may act to decommis-
sion Th2 enhancers. As is the case for FOXP3 and its
interaction partners, one could imagine that a change
in the relative levels of T-bet or GATA3 could shift
the balance and allow GATA3 to bind to Th2 sites.
Thus, the maintenance of GATA3 expression in
human Th1 cells, but in an alternative distribution,
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may allow expression of a Th1 phenotype while
maintaining a degree of functional plasticity.
T-bet has a similar relationship with the Tfh-
specifying factor BCL6. These two proteins are co-
expressed during early Th1 development and in a
subset of Tfh cells [35–38]. T-bet directly interacts
with BCL6 and targets it to T-bet binding elements
where the T-bet–BCL6 complex acts repressively
(Figure 1F—Modulation). Interestingly, T-bet
binds the BCL6 zinc finger DNA-binding domain,
preventing BCL6 from contacting DNA at its ca-
nonical sites [37, 38]. Thus, T-bet may also interact
with GATA3 through its zinc finger DNA-binding
domain and thereby similarly occlude GATA3
DNA-binding activity. In cardiac cells, the T-box
protein TBX5 interacts with GATA4 through its
DNA binding domain [91], suggesting this form of
interaction between T-box factors and co-expressed
GATA family members is a common mechanism
controlling mammalian developmental processes. In
addition to its altered genomic distribution in Th1
cells, GATA3 also exhibits different patterns of bind-
ing in other CD4þ T cell lineages [92] and during
earlier stages of T cell development [93], implying
that other lineage-specific factors act to alter GATA3
binding to allow other changes in the T cell
differentiation state. Analysis of motifs at these sites
suggests that these other co-factors could be members
of the Runx, Ets and AP-1 families [92]. Interestingly,
GATA3 has different effects on gene activity and
chromatin modification in different cells, suggesting
that co-factors also act to modulate its activity [92].
Thus, the lineage-specific effects of GATA3 may pri-
marily be a function of its interplay with other factors
rather than a reflection of its own inherent activity.
SUMMARYANDOUTLOOK
Although limited to classifying cells by the expression
of a handful of proteins, classical cellular immunolo-
gical methods have been very useful in defining the
archetypal helper T cell lineages and identifying the
major signals and transcriptional regulators involved
in their generation. However, the resultant model
that helper T cells can differentiate into one of a
number of distinct terminally-differentiated lineages
has not been supported by more recent findings.
Functional genomics methods are playing a key
role in revealing the complex interplay that exists
between helper T cell transcriptional regulators and
the spectrum of cell phenotypes and plasticity that
this creates (Figure 2).
Figure 2: Summary of T cell differentiation control through transcription factor interplay. The extracellular envir-
onment is sensed by the cell through antigens and cytokines (1). TCR signalling leads to activation of general acting
pioneer (GP) transcription factors, such as NFATand AP-1 (2). In addition, the cytokine milieu causes activation of
cytokine-specific pioneers (CSP), such as STATs (3). Together, these pioneers influence genome-wide enhancer com-
petency (4) and the expression of a lineage-specifying factor (LSF1) (5). Interplay between the lineage-specifying
transcription factor, co-factors and the pre-existing chromatin landscape results in a lineage-specific gene expres-
sion program (6). Transcription factors associated with other lineages (LSF2) may also be expressed (7), allowing
modulation of the cell phenotype and cell plasticity.
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Ligation of the TCR by antigen leads to activa-
tion of general pioneer factors such as NFAT and
AP1 (Figure 2). These regulators act with STATs
activated in specific patterns in response to cytokine
signalling to prepare the activated T cell chromatin
landscape. Different STATs lead to activation of dif-
ferent distal regulatory elements, providing a direct
link between the cellular microenvironment and epi-
genetic regulation. Clearly, the microenvironment of
a T cell in vivo will be much more complex than
those used in in vitro differentiation models, leading
to the activation of a correspondingly more complex
transcriptional regulatory network and a more
nuanced cell phenotype that reflects the balance of
these input signals. The subsequent expression of
lineage-specifying factors focuses cell fate, reinfor-
cing a specific lineage choice while closing down
potential alternative differentiation pathways. The
lineage-specifying factors do not appear to have as
fundamental effects on the epigenetic landscape as
the pioneer factors, consistent with the requirement
for the continued expression of these proteins to
maintain cell state and the plasticity that is evident
between lineages.
The signals received often lead to co-expression
of more than one lineage-specifying factor. We are
beginning to define the regulatory mechanisms
that govern their interplay in these situations.
There is clearly a regulatory ‘tug-of-war’ between
co-expressed factors, often mediated by direct inter-
action that can lead to changes in transcription factor
binding or activity. The relative levels between
the factors would appear to be important in defining
which factor ‘wins out’ but there also seems to be
a regulatory hierarchy in which certain factors
act dominantly over others. The outcome of these
interactions is often a hybrid gene expression pro-
gram, for example, allowing cells to take on features
of more than one effector or to adopt a suppressor
phenotype with a polarized homing activity
(Figure 2). Changes in the cellular environment
then allow for a change in the balance of power
between co-expressed regulators. Thus, this mech-
anism not only provides a defined cell phenotype,
Figure 3: Changing consideration of different Th lineages to points within Th space. (A) The traditional view of
T cell lineage specification downstream of ligation of theT cell receptor of na|º ve CD4+ T cells. Depending on the
cytokine signals received, the cell can differentiate down one of several discrete pathways, leading to a set of dis-
tinct, non-overlappingT cell lineages, shown here forTh1, Th2 and Treg subtypes. Each lineage expresses a different
master regulator transcription factor and produces a signature set of cytokines. (B) It may be more appropriate to
consider na|º ve CD4+ T cells as having a wide range of possible fates, which can be classified according to the
degree to which they are polarized along multiple axes, such as ‘Th1-ness’, ‘Th2-ness’ or ‘Treg-ness’, each of which is
controlled by different network of factors. This creates a ‘Th-space’ in which the different cell phenotypes exist as
relatively stable low energy points. Limited by the page, this space is shown here as a 3-dimensional cone, but the
true number of potential dimensions along which a cell can polarize is not yet known.The degree to which a cell is
polarized along each axis is a product of the balance of the signals received and the interplay between the resultant
factors induced. Cells cross a differentiation boundary when activated (dashed circle), which they cannot re-cross,
and migrate to a position within Th-space that dictates their phenotype. Cells maintain the potential to move
withinTh-space to adopt different phenotypes (plasticity) but may still be able to reach a stage of terminal differen-
tiation at which their phenotype becomes fixed (represented by the plane at the end of the cone).
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but also allows the cell to respond to changing en-
vironmental conditions.
Considering these developments, it may not be
appropriate to apply terms such as ‘Th1’, ‘Th2’ and
‘Treg’ to different cell lineages that can differentiate
along distinct pathways from a naı¨ve T cell
(Figure 3A). It may instead be more helpful to con-
sider ‘Th1’, ‘Th2’ and ‘Treg’ as properties or gene
expression modules that cells can possess to varying
extents (Figure 3B). For example, a FOXP3þT-
betþ cell has both Treg and Th1 qualities. In this
way, cells lie in different points within a multi-di-
mensional ‘Th space’ rather than at the ends of dif-
ferent linear pathways, with some points within this
space being more stable (lower energy) than others
(Figure 3B).
There is clearly much to do before we understand
the mechanisms controlling transcription factor
interplay, the differences in epigenetic modification
and gene activity this causes and the resultant cell
phenotypes produced. It will be necessary to com-
bine reductionist approaches to define the mechan-
isms through which factors interact, the changes in
gene activity this causes and then annotating these
mechanisms onto system-wide views. These systems
models could then be tested by disrupting individual
regulator–regulator interactions in specific cell types.
A greater focus on the molecular mechanisms
through which T cell transcription factors act may
be of advantage. We often think of transcription
factors as black boxes that bind DNA and activate
or represses transcription but different factors achieve
this in different ways and a greater knowledge of the
specific epigenetic and transcriptional states affected
by each factor will be of great use in understanding
how their activities synergize or antagonize to gener-
ate a gene expression program. The study of factors
such as T-bet, GATA3 and FOXP3 in other cell types
will also aid the identification of the molecular events
these factors control. By extending studies to innate
lymphoid cells, can we define T-betness, beyond ac-
tivation of Ifng? Is there something GATA3 does in
both T cells and mammary luminal epithelium [94]?
Does FOXP3 also interact with the same set of co-
factors to modulate cell fate in the epithelium of the
prostate, breast, lung and ovary [95]?
Technologies that will enable these advances in-
clude the ability to trace cell lineages invivo and then
characterize individual progeny cells using multi-
colour-flow and single-cell RNA quantification
[96]. This will be specifically important to define
the potential cell phenotypes available from a given
starting population, and to quantify their relative
frequency and association with different microenvir-
onments. Genome-wide sequential ChIP (ChIP-
reChIP) will also identify the genomic sites at
which different transcription factor complexes are
positioned. Do FOXP3–IRF4 complexes bind at
different sites to FOXP3–GATA3 complexes and
do the different binding partners lead to different
local histone modifications and associated changes
in gene activity? The ability to perform ChIP-Seq
on single cells is some way off but genetic modifica-
tion to tag transcription factors in a cell-type-specific
manner would allow transcription factor binding to
be measured in a specific cell type when present
within a mixed-cell population. The use of genomics
methods to identify alterations to T cell states in
human disease conditions and the identification of
polymorphisms affecting transcription factor binding,
will allow us to link pathology to changes in specific
regulatory mechanisms. Such insights may also allow
development of new strategies to alter the helper T
cell differentiation state to relieve autoimmune or
allergic conditions, to specify the phenotypes of
adoptively transferred cells and enhance sub-optimal
immune responses.
Key Points
 Regulation of helperT cell lineage specification is more complex
and plastic than previously appreciated.
 T cell transcriptional factors tend to occupy commonregulatory
elements, with non-lineage specific factors and STATs acting as
pioneers.
 Lineage-specifying regulators functionwith an extensive array of
co-factors in complex regulatory networks.
 Lineage-specifying factors such asT-bet,GATA3 and FOXP3 are
frequently co-expressed in different lineages and the balanced
interplay between them dictates the resultant cell state.
 Different T cell lineages canbe thoughtof as pointswithinmulti-
dimensional ‘Th space’, defined by the degree to which they are
polarized along different axes.
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